tbuckley/cabot-search huggingface dataset:
Neuroendocrine tumor disease state and PROMIS health-related quality of life scores.
Authors: D. Cella, J. L. Beaumont, Z. Liu, A. T. Phan, S. Choi, J. C. Yao
Journal: Journal of Clinical Oncology (2010)

6118 Background: Health-related quality of life (HRQL) can be disrupted in patients (pts) with malignancies. The objective of this study was to compare the HRQL burden of pts with neuroendocrine tumor (NET) in different disease states relative to the general population. Methods: Pts with NET were invited via email to participate in an online anonymous survey. The survey consisted of demographic and disease-related questions and two standardized measures of HRQL (RAND-36 and PROMIS-29). Scores for U.S. general population are normalized to 50. PROMIS scores were compared using analysis of variance among 3 groups: pts with no tumor currently present (e.g., surgically removed)—no current NET; pts with tumor that has not been surgically removed or has come back after surgery—current NET, but without carcinoid syndrome; current NET with carcinoid syndrome. Score differences of 2.5-5.0 points are generally regarded as clinically meaningful. Lower scores on the physical function and social role scales of the PROMIS indicate worse HRQL. Higher scores on other scales indicate worse HRQL. Results: A total of 663 pts participated and demonstrated worse HRQL scores compared to the general population on all subscale scores of the PROMIS-29 (all p<.01). Of these, 526 provided complete information on current NET and carcinoid syndrome. 443/526 (84%) pts had NET present, of these, 328/443 (74%) had carcinoid syndrome. Compared to pts with no current NET, pts with current NET had significantly worse HRQL scores and those with carcinoid syndrome reported the worst (Table, all p<0.01). Conclusions: Pts with current NET and carcinoid syndrome report worse HRQL compared to pts without carcinoid syndrome, which in turn report worse HRQL than those without current NET. Optimal management of NET and carcinoid syndrome may significantly improve HRQL among pts with NETs. Further analysis of treatment effect on HRQL is warranted. Mean PROMIS- 29 scores No current NET n = 83 Current NET, no carcinoid syndrome n = 115 Current NET + carcinoid syndrome n = 328 All n = 663 Physical function 52 47 43 45 Anxiety 51 53 55 54 Depression 48 50 53 52 Fatigue 48 52 57 55 Pain interference 46 50 54 52 Sleep Disturbance 48 49 54 52 Social role 53 48 45 46 Scores for U.S. general population normalized to 50. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis Novartis Novartis
BMA meeting: Early dementia diagnosis is pointless without support services
Authors: Abi Rimmer
Journal: BMJ (2016)

An early diagnosis of dementia is pointless if there is no relevant support available for patients and their families, the BMA has said.

Doctors at the BMA’s annual representatives meeting in Belfast on Wednesday 22 June voted in favour of a motion that said that the “government’s drive for early diagnosis of dementia without the corresponding support for those who receive such a diagnosis is pointless.”

The motion said that making a diagnosis without support being available “only serves to increase distress for patients and families.”

Proposing the motion, GP Alex Freeman said that dementia was a terminal disease, but patients did not have the same access to …
Interferon-Induced Spermidine-Spermine Acetyltransferase and Polyamine Depletion Restrict Zika and Chikungunya Viruses
Authors: Bryan C. Mounce, Enzo Z. Poirier, Gabriella Passoni, Etienne Simon-Loriere, Teresa Cesaro, Matthieu Prot, Kenneth A. Stapleford, Gonzalo Moratorio, Anavaj Sakuntabhai, Jean-Pierre Levraud, Marco Vignuzzi
Journal: Cell Host & Microbe (2016)
Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development
Authors: Halie M. Anderson, Robert F. Lemanske, Joseph R. Arron, Cecile T.J. Holweg, Victoria Rajamanickam, Ronald E. Gangnon, James E. Gern, Daniel J. Jackson
Journal: Journal of Allergy and Clinical Immunology (2016)
Ex-Vivo Expansion and Prophylactic Infusion of CMV pp65 Specific CTL Following Haemopoietic Stem Cell Transplantation (HSCT).
Authors: David J. Gottlieb, Anna M. Hansen, Ken P. Micklethwaite, Aaron E. Foster, Cameron J. Turtle, Vicki Antonenas, Mary M. Sartor, Ken F. Bradstock
Journal: Blood (2005)
The Clinical Phenotype of Patients with Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis Whom Only Manifest WHO Grade 1 Fibrosis
Authors: Krisstina L. Gowin, Amylou Constance Dueck, Srdan Verstovsek, Naval Daver, Naveen Pemmaraju, Riccardo Valdez, Ruben A. Mesa
Journal: Blood (2014)
HIV Clinic
Authors: Eric P Walker
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).
Authors: Susan O’Brien, Thomas J. Kipps, Stefan Faderl, Michael Crump, Michael J. Keating, Blanche Anderson, Claudia Soho, Jan Bole, Ruth Turner, Jean Viallet, Bruce D. Cheson
Journal: Blood (2005)
Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit
Authors: G Chouinard, L Annable
Journal: American Journal of Psychiatry (1976)

The authors compared penfluridol, a long-acting neuroleptic that can be administered orally once a week, with chlorpromazine in the treatment of 33 newly admitted schizophrenic patients in a brief therapy unit. Patients receiving either drug improved enough to be discharged in 3 weeks. Penfluridol-treated patients experienced less drowsiness than those treated with chlorpromazine, but the severity of extrapyramidal symptoms appeared to be greater with penfluridol.
High Level of Fasting Plasma Proenkephalin-A Predicts Deterioration of Kidney Function and Incidence of CKD
Authors: Christina-Alexandra Schulz, Anders Christensson, Ulrika Ericson, Peter Almgren, George Hindy, Peter M. Nilsson, Joachim Struck, Andreas Bergmann, Olle Melander, Marju Orho-Melander
Journal: Journal of the American Society of Nephrology (2016)

High levels of proenkephalin-A (pro-ENK) have been associated with decreased eGFR in an acute setting. Here, we examined whether pro-ENK levels predict CKD and decline of renal function in a prospective cohort of 2568 participants without CKD (eGFR&gt;60 ml/min per 1.73 m 2 ) at baseline. During a mean follow-up of 16.6 years, 31.7% of participants developed CKD. Participants with baseline pro-ENK levels in the highest tertile had significantly greater yearly mean decline of eGFR ( P trend &lt;0.001) and rise of cystatin C ( P trend =0.01) and creatinine ( P trend &lt;0.001) levels. Furthermore, compared with participants in the lowest tertile, participants in the highest tertile of baseline pro-ENK concentration had increased CKD incidence (odds ratio, 1.51; 95% confidence interval, 1.18 to 1.94) when adjusted for multiple factors. Adding pro-ENK to a model of conventional risk factors in net reclassification improvement analysis resulted in reclassification of 14.14% of participants. Genome-wide association analysis in 4150 participants of the same cohort revealed the strongest association of pro-ENK levels with rs1012178 near the PENK gene, where the minor T-allele associated with a 0.057 pmol/L higher pro-ENK level per allele ( P =4.67x10 −21 ). Furthermore, the T-allele associated with a 19% increased risk of CKD per allele ( P =0.03) and a significant decrease in the instrumental variable estimator for eGFR ( P &lt;0.01) in a Mendelian randomization analysis. In conclusion, circulating plasma pro-ENK level predicts incident CKD and may aid in identifying subjects in need of primary preventive regimens. Additionally, the Mendelian randomization analysis suggests a causal relationship between pro-ENK level and deterioration of kidney function over time.
Policy Framework for Covering Preventive Services Without Cost Sharing
Authors: Stephanie C. Chen, Steven D. Pearson
Journal: JAMA Internal Medicine (2016)

The US Affordable Care Act mandates that private insurers cover a list of preventive services without cost sharing. The list is determined by 4 expert committees that evaluate the overall health effect of preventive services. We analyzed the process by which the expert committees develop their recommendations. Each committee uses different criteria to evaluate preventive services and none of the committees consider cost systematically. We propose that the existing committees adopt consistent evidence review methodologies and expand the scope of preventive services reviewed and that a separate advisory committee be established to integrate economic considerations into the final selection of free preventive services. The comprehensive framework and associated criteria are intended to help policy makers in the future develop a more evidence-based, consistent, and ethically sound approach.
Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance
Authors: Justin Taylor, Sunhee S. Kim, Kristen E. Stevenson, Akinori Yoda, Nadja Kopp, Abner Louissaint, Nancy Lee Harris, Ephraim P. Hochberg, Yi-Bin Chen, Scott B. Lovitch, Daniel J DeAngelo, Martha Wadleigh, David P. Steensma, Gabriela Motyckova, Richard M. Stone, Donna S. Neuberg, Fabrice Jardin, Pier Paolo Piccaluga, David M. Weinstock, Andrew A. Lane
Journal: Blood (2013)
Plasmablastic Lymphoma : A Case Series of the Changing Epidemiology of a Rare Extramedullary Plasmacytoid Neoplasm, Diagnostic Challenges, and Therapeutic Implications
Authors: Lisa X. Lee, Bhavana Konda, Amer Assal, Monica I Zell, Ira Braunschweig, Olga Derman, Noah Kornblum, Amit Verma, Ramakrishna Battini, Murali Janakiram
Journal: Blood (2014)
Tumor necrosis factor alpha (TNF alpha) downregulates c-kit proto- oncogene product expression in normal and acute myeloid leukemia CD34+ cells via p55 TNF alpha receptors
Authors: E Khoury, C Andre, S Pontvert-Delucq, B Drenou, C Baillou, M Guigon, A Najman, FM Lemoine
Journal: Blood (1994)
New test could help 40 000 pregnant rhesus D negative women avoid treatment, says NICE
Authors: Zosia Kmietowicz
Journal: BMJ (2016)

A new test that identifies which pregnant women who are rhesus D negative need to be treated could save the NHS £500 000 (€600 000; $666 000) a year.

Draft guidance from the National Institute for Health and Care Excellence (NICE)1 recommends that only those women who are rhesus D negative and carrying a rhesus D positive baby should be treated with anti-D immunoglobulin. If the proposal is adopted, treatment could be avoided in 40 000 women, NICE has said.

Currently, all women who are rhesus …
T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Yuji Ikeda, Jae-Hyun Park, Takashi Miyamoto, Naofumi Takamatsu, Taigo Kato, Akiko Iwasa, Shuhei Okabe, Yuichi Imai, Keiichi Fujiwara, Yusuke Nakamura, Kosei Hasegawa
Journal: Clinical Cancer Research (2016)

Abstract Background: We aimed to clarify the clinical significance of TOPK (T-lymphokine–activated killer cell–originated protein kinase) expression in ovarian cancer and evaluate the possible effect of TOPK inhibitors, OTS514 and OTS964, on ovarian cancer cells. Methods: TOPK expression was examined by immunohistochemistry using 163 samples with epithelial ovarian cancer (EOC). TOPK protein level and FOXM1 transcriptional level in ovarian cancer cell lines were examined by Western blot and RT-PCR, respectively. Half-maximum inhibitory concentration (IC50) values against TOPK inhibitors were examined by the MTT assay. Using the peritoneal dissemination model of ES-2 ovarian cancer cells, we examined the in vivo efficacy of OTS514. In addition, the cytotoxic effect of OTS514 and OTS964 on 31 patient-derived primary ovarian cancer cells was examined. Results: TOPK was expressed very highly in 84 (52%) of 163 EOC tissues, and high TOPK expression was significantly associated with poor progression-free survival and overall survival in early-stage cases of EOC (P = 0.008 and 0.006, respectively). Both OTS514 and OTS964 showed significant growth-inhibitory effect on ovarian cancer cell lines with IC50 values of 3.0 to 46 nmol/L and 14 to 110 nmol/L, respectively. TOPK protein and transcriptional levels of FOXM1 were reduced by TOPK inhibitor treatment. Oral administration of OTS514 significantly elongated overall survival in the ES-2 abdominal dissemination xenograft model, compared with vehicle control (P &amp;lt; 0.001). Two drugs showed strong growth-inhibitory effect on primary ovarian cancer cells regardless of tumor sites or histological subtypes. Conclusions: Our results demonstrated the clinical significance of high TOPK expression and potential of TOPK inhibitors to treat ovarian cancer. Clin Cancer Res; 22(24); 6110–7. ©2016 AACR.
RM-007 Chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone before surgery in patients with rectal cancer, experience of Medical Center 20 de Noviembre Mexico City
Authors: J. Mora Perez, C. Novales, A. Vargas Melendez, S. Cortes Cardenas, L. Torrecillas Torres
Journal: Annals of Oncology (2016)
KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.
Authors: Dean F. Bajorin, Elizabeth R. Plimack, Arlene O. Siefker-Radtke, Toni K. Choueiri, Ronald De Wit, Guru Sonpavde, Adrianna Gipson, Holly Brown, Yabing Mai, Lei Pang, Rodolfo F. Perini, Joaquim Bellmunt
Journal: Journal of Clinical Oncology (2015)

TPS4572 Background: Standard first-line therapy for advanced urothelial cancer is cisplatin-based chemotherapy. Pts who are ineligible for cisplatin therapy, mainly due to renal dysfunction and/or poor performance status, have limited treatment options. The programmed death receptor 1 (PD-1) pathway is used by tumors to suppress immune control. Pembrolizumab is a highly selective, IgG4 anti-PD-1 humanized monoclonal antibody designed to block the interaction between PD-1 and its ligands PD-L1 and PD-L2. In the phase 1 KEYNOTE-012 trial, pembrolizumab 10 mg/kg once every 2 weeks (Q2W) demonstrated an ORR of 24% (RECIST v1.1, central review) in 33 pts with PD-L1–positive advanced urothelial cancer, 76% of whom received ≥ 1 prior therapy. Methods: KEYNOTE-052 (ClinicalTrials.gov, NCT02335424) is an international, open-label, phase 2 trial of pembrolizumab 200 mg Q3W as first-line therapy for adults with unresectable or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra who are ineligible to receive cisplatin. Pts are considered cisplatin ineligible if they have ≥ 1 of the following: ECOG PS 2, creatinine clearance (calculated or measured) < 60 but ≥ 30 mL/min, grade ≥ 2 (CTCAE v4) audiometric hearing loss or peripheral neuropathy, or NYHA class III heart failure. All pts must provide a recently obtained biopsy sample for PD-L1 evaluation at a central laboratory. Pembrolizumab will be given for up to 24 mo or until disease progression, unacceptable toxicity, or investigator decision; treatment may be discontinued following complete response. Select pts may continue pembrolizumab beyond initial evidence of radiographic progression. Response will be evaluated per RECIST v1.1 by independent central review at 9 wk and every 6 wk thereafter. Survival follow-up will occur every 3 mo. Primary end point is ORR in pts with PD-L1–dependent tumors. Secondary end points include ORR in all pts, PFS, OS, duration of response, and the association between PD-L1 positivity and ORR. Up to 350 pts will be enrolled. KEYNOTE-052 is currently enrolling pts. Clinical trial information: NCT02335424.
A Phase I/II Combination Of RAD001 (Everolimus) and Lenalidomide For Relapsed Lymphoid Malignancy: Phase I Results
Authors: Craig Reeder, Amylou Constance Dueck, Katherine Gano, Craig Nichols, Angela Toro, Daniel Johnson, Patrick B. Johnston, Thomas M. Habermann, Jose F Leis, Grzegorz S. Nowakowski, Joseph Mikhael, Joseph Colgan, Luis F. Porrata, James L Slack, Stephen M Ansell, Thomas E Witzig
Journal: Blood (2013)
A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
Authors: A. Patnaik, L. J. Appleman, J. M. Mountz, R. K. Ramanathan, M. Beeram, A. W. Tolcher, K. P. Papadopoulos, M. T. Lotze, D. P. Petro, C. Laymon, L. Paige, P. Rajagopalan, M. Jeffers, D. Roth, R. L. Dubowy
Journal: Journal of Clinical Oncology (2011)

3035 Background: BAY 80-6946 is a potent and highly selective reversible pan-Class I PI3K inhibitor with anti-tumor activity in a panel of preclinical models. A phase I dose escalation multicenter study was initiated to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics (PD) in patients (pts) with advanced solid tumors. Methods: 17 nondiabetic pts received BAY 80-6946 1-hr intravenous infusions at doses of 0.1 mg/kg (1), 0.2 mg/kg (3), 0.4 mg/kg (3), 0.8 mg/kg (8) and 1.2 mg/kg (2). A cycle consists of 3 weekly doses, every 4 weeks, with treatment continuing until disease progression or unacceptable toxicity. Tumor types included 3 sarcoma, 3 pancreatic, 2 esophageal (Es), 2 endometrial (En) and 7 others. PK was evaluated following the first and third doses. FDG-PET/CT scans were performed at baseline and 48 hrs after the first dose to assess tumor specific PD. Safety evaluations included monitoring of glucose and blood pressure, EKGs and MUGA scans. Plasma and tumor DNA mutational analysis is ongoing. Results: PD effect of increase in post-infusion fasting insulin was seen starting at 0.2 mg/kg. The MTD was 0.8 mg/kg. At the MTD, 6 of 7 evaluable pts received insulin for glucose ≥ 200 mg/dL, but only within 24 hours of dosing. Other drug-related AEs include Gr 1/2 fatigue, nausea, vomiting, alopecia, diarrhea, mucositis and dysgeusia and Gr 2/3 anemia. One pt needed treatment for Gr 2 acute hypertension (0.4 mg/kg). DLT was seen in 1 pt at 1.2 mg/kg consisting of Gr 4 acute left ventricular dysfunction with lactic acidosis, liver dysfunction and renal insufficiency, and Gr 4 hyperglycemia, all recovering within several days. Stable disease (SD) for 6 mo (Es) and 8 mo (En) were observed. At 0.8 mg/kg, FDG uptake was reduced by 23% in a liver lesion of a pancreatic pt and 40% in a NSCLC lesion. At the MTD, the mean T1/2 was 38 hr and exposure was generally dose proportional. Conclusions: BAY 80-6946 was generally well tolerated through the MTD of 0.8 mg/kg. PK results support weekly dosing. Grade 2/3 hyperglycemia in the first 24 hrs after receiving a dose is common at the MTD. PK, clinical SD and FDG-PET data are consistent with effective exposure and PI3K pathway inhibition.
Improved survival in rheumatoid arthritis: a general population-based cohort study
Authors: Yuqing Zhang, Na Lu, Christine Peloquin, Maureen Dubreuil, Tuhina Neogi, J Antonio Aviña-Zubieta, Sharan K Rai, Hyon K Choi
Journal: Annals of the Rheumatic Diseases (2016)

Mortality trends of rheumatoid arthritis (RA) are largely unknown over the past decade when new drugs and management strategies have been adopted to effectively treat RA.Using The Health Improvement Network, an electronic medical record database representative of the UK general population, we identified patients with incident RA and up to five individuals without RA matched for age, sex and year of diagnosis between 1999 and 2014. The RA cohort was divided in two sub-cohorts based on the year of RA diagnosis: the early cohort (1999-2006) and the late cohort (2007-2014). We compared mortality rates, HRs (using a Cox proportional hazard model) and rate differences (using an additive hazard model) between RA and non-RA cohorts adjusting for potential confounders.Patients with RA diagnosed between 1999 and 2006 had a considerably higher mortality rate than their comparison cohort (ie, 29.1 vs 18.0 deaths/1000 person-years), as compared with a moderate difference in patients with RA diagnosed between 2007 and 2014 and their comparison cohort (17.0 vs 12.9 deaths/1000 years). The corresponding absolute mortality rate differences were 9.5 deaths/1000 person-years (95% CIs 7.5 to 11.6) and 3.1 deaths/1000 person-years (95% CI 1.5 to 4.6) and the mortality HRs were 1.56 (95% CI 1.44 to 1.69) and 1.29 (95% CI 1.17 to 1.42), respectively (both p values for interaction <0.01).This general population-based cohort study indicates that the survival of patients with RA has improved over the past decade to a greater degree than in the general population. Improved management of RA and its associated comorbidities over recent years may be providing a survival benefit.
Chemotherapy Combined with Granulocyte Colony Stimulating Factor (G-CSF) for Mobilization of CD34+ Cells in Lymphoma and Multiple Myeloma Patients
Authors: Gaofeng Zheng, Yanlong Zheng, Yi Luo, Jimin Shi, Weiyan Zheng, Guoqing Wei, Jie Sun, He Huang, Zhen Cai, Jingsong He
Journal: Blood (2015)
Case 14-1977
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, John F. Crigler, Robert E. Scully
Journal: New England Journal of Medicine (1977)

Presentation of CaseA five-year-old boy was admitted to the hospital because of hypospadias.He was born of a first pregnancy, which was complicated by toxemia. Labor was induced one month prematurely; the birth weight was 2.1 kg. Perineoscrotal hypospadias was observed at birth. A karyotype showed a normal male pattern. At the age of 16 months an intravenous pyelographic examination, performed elsewhere, was reported to be negative. A chordee was repaired in another hospital. Three and a half months before admission he was first seen at this hospital. The height was 105.4 cm (10th percentile), the weight 17.3 kg . . .
Studies must show the value of regulatory schemes
Authors: Ian G Wilson
Journal: BMJ (2016)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Studies must show the value of regulatory schemes Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.